Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene mutation may unlock L-Carnitine's power for sperm health

NCT ID NCT07402759

Disease control Sponsor: South Valley University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether men with a specific gene mutation (TDRD9) get more benefit from L-carnitine, a common supplement, to improve sperm count and movement. About 50 men with low sperm count and motility will take L-carnitine for 3 months. Researchers will compare changes in sperm quality between those with and without the mutation to see if genetics can guide personalized infertility treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

50 people

The number who actually took part.

Started

Jan 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Male participants aged 20-50 years Clinical diagnosis of oligoasthenozoospermia, confirmed by two semen analyses according to WHO 2010/2021 criteria: Sperm concentration \<15 million/mL, and Progressive motility \<32% Attempting conception with a partner for ≥12 months, or referred for infertility evaluation Willing and able to take oral L-carnitine and comply with all study visits and procedures Able and willing to provide written informed consent, including consent for genetic testing (TDRD9 analysis) Exclusion Criteria Known obstructive azoospermia Grade III varicocele requiring surgical correction, unless repaired ≥6 months prior to enrollment Use of fertility supplements or hormonal therapy within the 3 months prior to enrollment (washout required) Active genitourinary infection (e.g., prostatitis) or systemic illness known to affect fertility Known severe systemic disease, including uncontrolled diabetes mellitus or severe hepatic or renal disease Known hypersensitivity or allergy to L-carnitine History of testicular cancer or receipt of chemotherapy within the past 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Male infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

male infertility oligoasthenoteratozoospermia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Male infertility Oligoasthenozoospermia

Contacts and locations

Locations

  • Qena university hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.